Literature DB >> 8142254

Detection of malignancy-associated metabolites in the sera of cancer patients by electron capture gas chromatography.

J B Brooks1, P L Almenoff, M I Daneshvar, A H Johnson, V J Spechart, M T Basta, S E Unger, J N King, B Schwartz.   

Abstract

A reliable test that detects malignancy and indicates response to therapy is needed. Frequency-pulsed electron-capture gas-liquid chromatography (FPEC-GLC), a selective analytical technique that is sensitive to 15 fmol quantities of metabolites, was used to analyse derivatised acidic chloroform extracts of sera from patients with biopsy-proven cancer, non-malignant infectious and non-infectious disease, and healthy controls. Two peaks designated P1 and P10, not found in serum from healthy controls (n = 7) or patients with non-malignant disease (n = 85), were detected in biopsy-proven samples (n = 52) from cancer patients. P1 and P10 were later shown by chemical and mass spectral studies to be carboxylic acids. When one or both of these peaks were detected in the sera of non-treated patients they were always associated with malignancy. In patients responding to therapy, a reduction or disappearance of these peaks was observed. Further, it was noted that P10 persisted or increased in sera of patients with progressive cancer not responding to therapy. We conclude that this test has potential in diagnosis and for following the response of the disease to therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142254      PMCID: PMC1968802          DOI: 10.1038/bjc.1994.127

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  NMR--another cancer-test disappointment.

Authors:  R Shulman
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

2.  Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors.

Authors:  P Okunieff; A Zietman; J Kahn; S Singer; L J Neuringer; R A Levine; F E Evans
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

3.  Proton nuclear magnetic resonance spectroscopy of plasma from healthy subjects and patients with cancer.

Authors:  T Engan; J Krane; O Klepp; S Kvinnsland
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

4.  Selective procedures for detecting femtomole quantities of tuberculostearic acid in serum and cerebrospinal fluid by frequency-pulsed electron capture gas-liquid chromatography.

Authors:  J B Brooks; M I Daneshvar; D M Fast; R C Good
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

5.  Analysis by gas chromatography of amines and nitrosamines produced in vivo and in vitro by Proteus mirabilis.

Authors:  J B Brooks; W B Cherry; L Thacker; C C Alley
Journal:  J Infect Dis       Date:  1972-08       Impact factor: 5.226

Review 6.  Review of frequency-pulsed electron-capture gas-liquid chromatography studies of diarrheal diseases caused by members of the family Enterobacteriaceae, Clostridium difficile, and rotavirus.

Authors:  J B Brooks
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

7.  Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.

Authors:  E T Fossel; J M Carr; J McDonagh
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

8.  Effects of tumor necrosis factor-alpha on peroxidation of plasma lipoprotein lipids in experimental animals and patients.

Authors:  J McDonagh; E T Fossel; R L Kradin; S M Dubinett; M Laposata; Y A Hallaq
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

Review 9.  Clinical utility of oncofetal proteins and hormones as tumor markers.

Authors:  P E Garrett; S R Kurtz
Journal:  Med Clin North Am       Date:  1986-11       Impact factor: 5.456

Review 10.  Use of serum tumor markers in cancer diagnosis and management.

Authors:  S E Bates; D L Longo
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.